Contributions
Abstract: EP1328
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Paediatric MS
Introduction: It is known that pediatric MS proceeds with a greater frequency of exacerbations and higher inflammatory activity compared with a later onset. Standard drugs have their age limitations and there is insufficient information on their effectiveness in children
Objective: to evaluate the effectiveness of standard injection therapy in pediatric MS.
Methods: The city center of the MS in St. Petersburg has been working since 2011. A total of 351 patients (9.6%) with onset before 18 years were registered in the database (about 4000 patients). Retrospectively, the data of 66 patients with pediatric MS, who fell ill in 2011 to 2017, were retrospectively evaluated (3.5% of registered MS debuts in adult patients during the same period) . The effectiveness of standard injection therapy (relapses and MRI activity) in the first 2 years of the disease was assessed. Statistical analysis was performed with the program GraphPad Prism v7.0.
Results: The ADEM-like onset was registered in 5 patients (7.5%). In 33 patients (50%) there were sensory disorders, in 30% of cases there were motor and coordination disorders, optic neuritis was performed only in 14% of patients. During 1 year of glatiramer acetate therapy 88% of patients (n = 8) had no relapses, but at 2 years - only 33% did not experience an exacerbation. With the 1 year use of interferon beta 1 a 44, 81% patients (n = 13) were stable, at 2 years of therapy - 67% had an exacerbation. In the low-dose interferon in 61% of patients (n = 8) had no relapses, at the end of 2 year - half of the patients were transferred to other therapy due to inefficiency. Most patients with ineffectiveness of GA or interferones received therapy in clinical trials (n = 12). 2 patients received mitoxantrone, 2 patients - natalizumab and 1 patient - rituximab with stabilization of MS activity. 5 patients are waiting escalation by natalizumab or alemtuzumab.
Conclusion: Fast enough standard injection therapy stops restraining inflammation in pediatric MS. 40% of children require a change in therapy by the end of the second year due to inefficiency (relapses and/or high radiological activity).
Disclosure: M Shumilina: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Novartis, Biocad, Sanofi/Genzyme, Roche, Johnson & Johnson/ Janssen, R-Pharm and Generium.
E Evdoshenko: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Biogen Idec, Sanofi, Genzyme and Generium.
Abstract: EP1328
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Paediatric MS
Introduction: It is known that pediatric MS proceeds with a greater frequency of exacerbations and higher inflammatory activity compared with a later onset. Standard drugs have their age limitations and there is insufficient information on their effectiveness in children
Objective: to evaluate the effectiveness of standard injection therapy in pediatric MS.
Methods: The city center of the MS in St. Petersburg has been working since 2011. A total of 351 patients (9.6%) with onset before 18 years were registered in the database (about 4000 patients). Retrospectively, the data of 66 patients with pediatric MS, who fell ill in 2011 to 2017, were retrospectively evaluated (3.5% of registered MS debuts in adult patients during the same period) . The effectiveness of standard injection therapy (relapses and MRI activity) in the first 2 years of the disease was assessed. Statistical analysis was performed with the program GraphPad Prism v7.0.
Results: The ADEM-like onset was registered in 5 patients (7.5%). In 33 patients (50%) there were sensory disorders, in 30% of cases there were motor and coordination disorders, optic neuritis was performed only in 14% of patients. During 1 year of glatiramer acetate therapy 88% of patients (n = 8) had no relapses, but at 2 years - only 33% did not experience an exacerbation. With the 1 year use of interferon beta 1 a 44, 81% patients (n = 13) were stable, at 2 years of therapy - 67% had an exacerbation. In the low-dose interferon in 61% of patients (n = 8) had no relapses, at the end of 2 year - half of the patients were transferred to other therapy due to inefficiency. Most patients with ineffectiveness of GA or interferones received therapy in clinical trials (n = 12). 2 patients received mitoxantrone, 2 patients - natalizumab and 1 patient - rituximab with stabilization of MS activity. 5 patients are waiting escalation by natalizumab or alemtuzumab.
Conclusion: Fast enough standard injection therapy stops restraining inflammation in pediatric MS. 40% of children require a change in therapy by the end of the second year due to inefficiency (relapses and/or high radiological activity).
Disclosure: M Shumilina: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Novartis, Biocad, Sanofi/Genzyme, Roche, Johnson & Johnson/ Janssen, R-Pharm and Generium.
E Evdoshenko: has recieved and dedicated to research support fees for board membership, consultancy or speaking, or grants, in the last 3 years from Biogen Idec, Sanofi, Genzyme and Generium.